General Information of Drug Transporter (DT)
DT ID	DTD0471 Transporter Info
Gene Name	SLC7A5
Protein Name	L-type amino acid transporter 1
Gene ID	8140
UniProt ID	Q01650
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs4240803
Site of GPD	chr16:87855597 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	A=0.4615/2311 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Melphalan	Drug Info	Multiple Myeloma	Correlated with the decreased gastrointestinal toxicity risk in patients (compare with genotype GG)		[ 1]
Melphalan	N.A.	Gastrointestinal Toxicity	Genotypes AA + AG is associated with decreased risk of gastrointestinal toxicity when treated with melphalan in people with Multiple Myeloma as compared to genotype GG.		[ 1]
Melphalan	N.A.	Multiple Myeloma	Genotypes AA + AG is associated with decreased risk of gastrointestinal toxicity when treated with melphalan in people with Multiple Myeloma as compared to genotype GG.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Gabapentin	N.A.	Substance-related Disorders	Genotype AG is associated with increased dose of gabapentin in people with neuropathic pain as compared to genotype GG.		[ 2]
Pregabalin	N.A.	Substance-related Disorders	Genotype AG is associated with decreased response to gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.		[ 2]
Gabapentin	N.A.	Adverse Events	Genotype AG is associated with increased risk of adverse events when treated with gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.		[ 2]
Pregabalin	N.A.	Adverse Events	Genotype AG is associated with increased risk of adverse events when treated with gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.		[ 2]
Gabapentin	N.A.	Neuropathic Pain	Genotype AG is associated with increased risk of adverse events when treated with gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.		[ 2]
Pregabalin	N.A.	Neuropathic Pain	Genotype AG is associated with increased risk of adverse events when treated with gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.		[ 2]
Melphalan	N.A.	Multiple Myeloma	Patients with the AG genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.		[ 1]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Pregabalin	N.A.	Substance-related Disorders	Allele A is not associated with dose of pregabalin in people with neuropathic pain as compared to allele G.		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Gabapentin	N.A.	Adverse Events	There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.		[ 2]
Gabapentin	N.A.	Neuropathic Pain	There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.		[ 2]
Pregabalin	N.A.	Adverse Events	There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.		[ 2]
Pregabalin	N.A.	Neuropathic Pain	There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.		[ 2]
Melphalan	N.A.	Multiple Myeloma	Patients with the AA genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Gabapentin	N.A.	Adverse Events	Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.		[ 2]
Gabapentin	N.A.	Neuropathic Pain	Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.		[ 2]
Pregabalin	N.A.	Adverse Events	Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.		[ 2]
Pregabalin	N.A.	Neuropathic Pain	Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.		[ 2]
Melphalan	N.A.	Multiple Myeloma	Patients with the GG genotype and multiple myeloma may have an increased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.		[ 1]
References
1	A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2014 Jul;20(7):1014-20.
2	Influence of single nucleotide polymorphism of LAT1 on therapeutic response to gabapentinoids in Pakistani patients with neuropathic pain. Basic Clin Pharmacol Toxicol. 2021 Mar;128(3):503-510.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.